Skip directly to site content Skip directly to search


Español  Other Languages


An official website of the United States government Here's how you know
 Official icon**Official websites use .gov**
				A .gov website belongs to an official government organization in the United States. Lock icon**Secure .gov websites use HTTPS**
				A lock (  ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
	CDC LogoCDC Logo
 Search

		×
			Vaccines site
			Vaccines site

				All CDC
				Submit


Advisory Committee on Immunization Practices (ACIP)





Evidence to Recommendations for MenACWY-TT (MenQuadfi) Meningococcal Vaccine						Print
																Related Pages
										**Question:**Policy question: Should MenACWY-TT (MenQuadfi) be included as an option for meningococcal ACWY vaccination according to currently recommended dosing and schedules?**Population:**Persons aged ≥ 2 years currently recommended to receive meningococcal conjugate (ACWY) vaccines**Intervention:**Vaccination with MenACWY-TT according to currently recommended dosing and schedules**Comparison(s):**Vaccination with MenACWY-D and MenACWY-CRM according to currently recommended dosing and schedules**Outcome(s)1:**
Short-term immune response
Persistence of immune response
Immune interference due to co-administration with other routine adolescent vaccines
Serious adverse events**Background:**
Meningococcal disease is an uncommon but severe bacterial infection that can progress rapidly. One in ten persons with meningococcal disease die despite proper antibiotic treatment, and one in five survivors have long-term sequelae.
Despite the current low incidence of meningococcal disease in the United States, certain groups are at increased risk for meningococcal disease. Serogroup A, C, W, Y (MenACWY) meningococcal vaccines are currently recommended for use in adolescents aged 11 – 18 years, persons with certain underlying conditions (persistent complement component deficiency, complement inhibitor (e.g., eculizumab [Soliris®]) use, anatomic or functional asplenia, and HIV), microbiologists with routine exposure to Neisseria meningitidis isolates, persons at increased risk due to a meningococcal disease outbreak caused by serogroup A, C, W, or Y, persons who travel to or reside in countries where meningococcal disease is endemic or hyperendemic, unvaccinated or under-vaccinated college freshmen living in residence halls, and military recruits.
MenACWY-TT (MenQuadfi, Sanofi-Pasteur) is a MenACWY conjugate vaccine that was approved in the United States in April 2020 for use in individuals aged 2 years or older. Considering availability of the newly licensed MenACWY-TT vaccine, the ACIP Meningococcal Vaccines Work Group assessed data related to potential benefits and harms of including MenACWY-TT as an option for meningococcal ACWY vaccination, including through the Vaccines for Children (VFC) program, according to currently recommended dosing and schedules. No changes to existing ACIP recommendations for use of meningococcal vaccines are proposed. Of note, several current ACIP recommendations for use of MenACWY vaccines are off-label for both the currently available MenACWY-CRM and MenACWY-D vaccines and for MenACWY-TT; these include the two-dose primary series for individuals with complement component deficiency, functional or anatomic asplenia, or HIV infection; booster doses in persons aged <15 years of age; and second and subsequent booster doses in individuals recommended to receive multiple booster doses due to persistent increased meningococcal disease risk. For MenACWY-D and MenACWY-CRM, use in persons aged >55 years is also off-label; however, MenACWY-TT is licensed in this age group.
A Grading of Recommendations, Assessment, Development, and Evaluation (GRADE) was completed for MenACWY-TT vaccine to assess the certainty of evidence. Additional factors related to MenACWY-TT vaccination were assessed as part of the Evidence to Recommendations Framework (EtR), summarized below.
Additional background information supporting the ACIP recommendations on the use of MenACWY vaccine can be found in the Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Recommendations and Reports and Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons — Advisory Committee on Immunization Practices, 2016.2Problem

Problem
Criteria
Work Group Judgments
EvidenceIs the problem of public health importance?
Yes
ACIP has recognized meningococcal disease as a problem of public health importance and currently recommends routine vaccination with quadrivalent conjugate (MenACWY) vaccines for adolescents and persons at increased risk of meningococcal disease. Current incidence of meningococcal disease in the United States is 0.1 cases per 100,000 population.
The Work Group was of the opinion that the question of whether to include MenACWY-TT vaccine as an option for meningococcal ACWY vaccination is probably of public health importance in the context of recent FDA licensure of MenACWY-TT.Show More
Benefits and Harms
Benefits and Harms
Criteria
Work Group Judgments
Research EvidenceHow substantial are the desirable anticipated effects?
Small
Inclusion of MenACWY-TT as an additional option for MenACWY vaccination will increase availability and choice for vaccine providers and recipients and increase security of vaccine supply.How substantial are the undesirable anticipated effects?
Minimal
The clinical trials for MenACWY-TT in healthy persons demonstrated an acceptable safety profile compared with currently available MenACWY vaccines.   No serious adverse events related to the MenACWY-TT vaccine were detected in any of the clinical trials. Immune responses to MenACWY-TT were non-inferior to those induced by licensed meningococcal vaccines, showing that addition of MenACWY-TT as an option for meningococcal vaccination will not reduce individual or population protection from meningococcal disease.
Concomitant administration of MenACWY-TT with other routine adolescent vaccines demonstrated non-inferiority of the immune response to HPV, tetanus, diphtheria, and pertussis toxin. Non-inferiority criteria were not met for other pertussis antigens; however, clinical relevance of this finding is unknown and similar issues have been noted with coadministration of Tdap and other licensed MenACWY vaccines.Do the desirable effects outweigh the undesirable effects?
Favors intervention
The desirable effects of MenACWY-TT, including additional options for providers and patients, and security of the supply chain, outweigh the undesirable effects as there is currently no evidence of safety, coadministration, or other concerns for use of MenACWY-TT.What is the overall certainty of this evidence for the critical outcomes?
**For healthy individuals:**
Effectiveness of the intervention
is Level 4 (Very low), Level 2 (Moderate), Level 1 (High)Safety of the intervention
is Level 2 (Moderate)
**For individuals at increased meningococcal disease risk because of specified underlying medical conditions:**
Effectiveness of the intervention is Level 4 (Very low), Level 3 (Low)
Safety of the intervention is Level 4 (Very low)
GRADE analysis was completed to assess certainty of evidence for inclusion of MenACWY-TT vaccine as an option for MenACWY vaccination according to currently recommended dosing and schedules.
Overall evidence type for adolescents and individuals at increased meningococcal disease risk for reasons other than underlying medical conditions was 1 for short-term immune response, 2 for immune interference due to co-administration of routine adolescent vaccines, 4 for persistence of the immune response, and 2 for serious adverse events.
Overall evidence type for individuals at increased meningococcal disease risk because of specified underlying medical conditions was 3 for short-term immune response, 4 for immune interference due to coadministration of routine adolescent vaccines, 4 for persistence of the immune response, and 4 for serious adverse events.See associated GRADE tables for additional details.Values
Values
Criteria
Work Group Judgments
Research EvidenceDoes the target population feel that the desirable effects are large relative to undesirable effects?
Yes
No data are available on values of the target population toward inclusion of MenACWY-TT as an additional option for MenACWY vaccination.
However, the high vaccination coverage of 86.6% in 2018 for at least one dose of MenACWY among adolescents demonstrates that the target population feels that the desirable effects of MenACWY vaccination outweigh the undesirable effects.3 Limited data are available on MenACWY vaccine uptake in other individuals recommended to receive MenACWY vaccine.Is there important uncertainty about or variability in how much people value the main outcomes?
Probably no important uncertainty or variability
High vaccination coverage of 86.6% in 2018 for at least one dose of MenACWY among adolescents demonstrates that the target population values the outcomes of vaccine immunogenicity and effectiveness for prevention of meningococcal disease. The Work Group feels confident that physicians and the general public also value the safety of meningococcal vaccines.Acceptability
Acceptability
Criteria
Work Group Judgments
Research EvidenceIs the intervention acceptable to key stakeholders?
Yes
No data are available on the acceptance of including MenACWY-TT as an option for MenACWY vaccination among key stakeholders. However, the high vaccination coverage for at least one dose of MenACWY among adolescents demonstrates acceptance of MenACWY vaccination among adolescents. Limited data are available on MenACWY vaccine uptake in other individuals recommended to receive MenACWY vaccine.Resource Use
Resource Use
Criteria
Work Group Judgments
Research EvidenceIs the intervention a reasonable and efficient allocation of resources?
Yes
MenACWY-TT cost is projected to be within 5% of currently licensed and available MenACWY conjugate vaccines in the United States. As such, resource allocation will not be substantively affected by the addition of MenACWY-TT as an option for meningococcal ACWY vaccination according to current recommendations.Feasibility
Feasibility
Criteria
Judgments
Research EvidenceIs the intervention feasible to implement?
Yes
Including MenACWY-TT as an option for MenACWY vaccination will not create any new feasibility challenges. Vaccination of adolescents relies on an existing vaccination platform and high coverage with at least one dose of MenACWY in adolescents demonstrates that implementing existing recommendations in this age group has been feasible.Balance of Consequences
Desirable consequences probably outweigh undesirable consequences in most settings
Is there sufficient information to move forward with a recommendation? Yes
Recommendation
MenACWY-TT (MenQuadfi) should be included as an option for meningococcal ACWY vaccination according to currently recommended dosing and schedules. Inclusion of MenACWY-TT as an option does not require an ACIP vote as no new recommendations are being made; however, a VFC vote will be needed to include this vaccine as an option in the Vaccines for Children program.
References
1Prevention and Control of Meningococcal Disease: Recommendations of the Advisory Committee on Immunization Practices (ACIP) Recommendations and ReportsMarch 22, 2013 / 62(RR02);1-22.https://www.cdc.gov/mmwr/preview/mmwrhtml/rr6202a1.htm
2 MacNeil JR, Rubin LG, Patton M, Ortega-Sanchez IR, Martin SW. Recommendations for Use of Meningococcal Conjugate Vaccines in HIV-Infected Persons — Advisory Committee on Immunization Practices, 2016. MMWR Morb Mortal Wkly Rep 2016;65:1189–1194. DOI: https://dx.doi.org/10.15585/mmwr.mm6543a3
3 Walker TY, Elam-Evans LD, Yankey D, et al. National, Regional, State, and Selected Local Area Vaccination Coverage Among Adolescents Aged 13–17 Years — United States, 2018. MMWR Morb Mortal Wkly Rep 2019;68:718–723. DOI: https://dx.doi.org/10.15585/mmwr.mm6833a2This Evidence to Recommendation table is based on the GRADE Evidence to Decision framework developed through the *DECIDE* project. See further information. Framework last updated 19 June 2019.
							
					
							Last Reviewed:  September 24, 2020						Source: 	National Center for Immunization and Respiratory Diseases
					Facebook
        Twitter
        LinkedIn
        Syndicate homeACIP Home
Meeting Information
Committee Informationplus icon
Role of the ACIP in CDC’s Vaccine Recommendations
Charter
Economics Studies
Committee Membersplus icon
ACIP Membership Roster
Apply for ACIP Membership
Work Groupsplus icon
VaST Reportsplus icon
June 28, 2021
May 24, 2021
May 17, 2021
March 29, 2021
Recommendationsplus icon
Shared Clinical Decision-Making Recommendations
Evidence Based Recommendationsplus icon
About GRADE
Grade Evidence Tables
Evidence to Recommendations Frameworks Error processing SSI file


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue